Storia in 2 fonti

FDA rejects Galderma’s relabotulinumtoxinA for second time

The FDA declined to approve a biologics license application for Galderma’s relabotulinumtoxinA, citing manufacturing and testing concerns, according to a company press release. In its complete response letter, the FDA stated that “observations during manufacturing site inspection and analytical method optimization” need to be addressed, according to the release. The agency did

Raccontata da

swissinfo.ch

healio.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

healio.comStai leggendo1 g fa

FDA rejects Galderma’s relabotulinumtoxinA for second time

originale

swissinfo.ch2 g fa

Galderma Slumps After FDA Turns Down Botox Rival Relfydess

(Bloomberg) -- Galderma Group AG shares slumped the most in more than a year after the US Food and Drug Administration turned down the Swiss dermatology firm’s rival Botox treatment Relfydess.

Leggi questa versione → originale

FDA rejects Galderma’s relabotulinumtoxinA for second time

Confronto fonti

FDA rejects Galderma’s relabotulinumtoxinA for second time

Galderma Slumps After FDA Turns Down Botox Rival Relfydess

Timeline cronologica

Galderma Slumps After FDA Turns Down Botox Rival Relfydess

FDA rejects Galderma’s relabotulinumtoxinA for second time

FDA rejects Galderma’s relabotulinumtoxinA for second time

Confronto fonti

FDA rejects Galderma’s relabotulinumtoxinA for second time

Galderma Slumps After FDA Turns Down Botox Rival Relfydess

Timeline cronologica

Galderma Slumps After FDA Turns Down Botox Rival Relfydess

FDA rejects Galderma’s relabotulinumtoxinA for second time